Sign Up
Stories
Biocytogen and Radiance Collaborate on Drug Conjugate
Share
ADC Therapeutics Webcast Announced
ADOCIA Files 2023 Registration Document
Adagene Advances Clinical Collaboration
ADC Therapeutics Reports Financial Progr...
Advanced Ovarian Cancer Treatment Breakt...
Biosimilar HLX14 Succeeds in Trials
Overview
API
Biocytogen Pharmaceuticals partners with Radiance Biopharma for the development of a bispecific antibody-drug conjugate targeting HER2/TROP2, aiming to expedite the commercialization of the product.
Ask a question
How might the development of this bispecific antibody-drug conjugate impact the treatment landscape for HER2/TROP2-positive cancers?
In what ways could this collaboration shape the future of targeted drug development for cancer?
What are the potential challenges and considerations for the development and commercialization of such a drug?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage